Abstract
Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for 18F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.
Original language | English (US) |
---|---|
Pages (from-to) | 327-339 |
Number of pages | 13 |
Journal | PET Clinics |
Volume | 5 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2010 |
Externally published | Yes |
Keywords
- Benign
- Fluorodeoxyglucose
- Malignant
- Multiple myeloma
- Positron emission tomography
- Sarcoma
ASJC Scopus subject areas
- Radiation
- Radiology Nuclear Medicine and imaging